Estimated Benefits of Atypical Antipsychotics in Schizophrenia: A Decision Model
2012
This article, published in Annals of General Psychiatry, describes the development of a decision tree model with Markov processes to quantify the resources used and the corresponding burden of disease due to a projected reduction in relapse frequency resulting from further improvements in medication compliance in patients with schizophrenia. The analyses are conducted from the third party payer perspective and outcomes are modeled over a one-year and five-year time horizon. Three delivery technologies are compared: a hypothetical delivery technology that prolongs the duration of action of an antipsychotic medication thereby permitting low frequency administration (LFA) antipsychotic therapy, risperidone generic standard oral therapy (RIS-SOT), and risperidone long-acting injection (RIS-LAI) formulations.
One-year findings of this study indicate that LFA therapy every 3 months (LFA-3) ($6,088) are less costly than either RIS-SOT ($10,721) or RIS-LAI ($9,450) with similar trends in the 5-year results. Moreover, the model predicts that LFA-3 vs. RIS-SOT vs. RIS LAI therapy reduces costly inpatient relapses (0.16 vs. 0.51 vs. 0.41). Extending the interval to six (LFA-6) and nine (LFA-9) months resulted in further reductions in relapse and costs.
The authors conclude that potential health state improvements and direct medical cost savings are achievable with the development and use of LFA medication delivery technologies.
Estimated Benefits of Atypical Antipsychotics in Schizophrenia: A Decision Model
Source:
Furiak NM, Gahn JC, Klein RW et al. Estimated Economic Benefits from Low-Frequency Administration of Atypical Antipsychotics in the Treatment of Schizophrenia: A Decision Model. Annals of General Psychiatry 2012; 11 (1): 29. https://doi.org/10.1186/1744-859X-11-29